

## Case Report

Open Access, Volume 2

# Disseminated TB bovis

### \*Corresponding Author: Adel Ekladious

Faculty of Health and Medical Sciences University of Western Australia 35 Stirling Hwy, Crawley, Western Australia. Royal Hobart Hospital, 48 Liverpool Street, Tasmania 7000, Australia.  
Tel: 61-499-449-905; Email: ekladiou@gmail.com

Received: May 09, 2022

Accepted: Jun 23, 2022

Published: Jun 30, 2022

Archived: www.jjgastro.com

Copyright: © Ekladious A (2022).

### Case report

50-year-old man presented to ED with frank total haematuria for three weeks and fever. His past medical history was unremarkable, he was up-to-date with vaccination including double dose Fizer vaccine and booster, he lives in Koala Lumper and works as a truck driver, he smokes for the last three years 15 cigarettes a day and drinks two glass of wine in the weekend and public holidays, he does not suffer from any medical condition and does not take any medication, he is married and was in monogamous relationship and has had two healthy children. On examination, he had a low grade fever 37.8, Blood Pressure 130/80, normal oxygen saturation on room air, systemic examination was unremarkable with no rash or arthritis, urine deep stick showed frank haematuria, no nitrates. The following investigation were done and were either normal or negative: FBC, Urea, electrolytes, immunoglobulin, PANCA, CANCA, anti GBM, serum IGA, Albumin creatinine ratio (from urine), ANA, DNA, ACCP, complements, LFT, corrected serum calcium. Patient had cystoscopy and multiple biopsy from the bladder, pathology confirmed high grade Urothelial tumour, immunohistochemistry confirmed the diagnosis, patient treated with transurethral resection, six months later, patient developed total haematuria,

### Abstract

Intravesical Bacillus Calmette- Guerin (BCG) still a popular medication for non-invasive bladder cancer in the low-income country, one of the uncommon side effects is disseminated Mycobacterium Bevis we present a patient who presented with haematuria, diagnosed as urothelial superficial bladder cancer, treated with incomplete resection and intravesical BCG, 6 months after treatment, he presented with increasing shortness of breath, headache and abdominal pain, diagnosed as tuberculous, meningitis, massive pleural effusion and granulomatous, he responded very well to anti tuberculous treatment.

cystoscopy confirmed recurrence of the tumour, whole body scan excluded any metastasis. Patient treated with surgery and intravesical BCG (live attenuated Bacille Calmette –Guerin) 6 months later patient presented to his GP with headache, low grade fever, abdominal pain and increasing shortness of breath, patient transferred to hospital for investigation and management. In ED patient was unwell with fever, neck pain, tachypnoea. On examination he had neck stiffness, fever 38, respiratory rate of 28/min, heart rate 110/minute, no rash, generalised arthralgia but no arthritis, congested sclera. Examination of the chest showed stony dullness in the right hemi thorax with decreased chest expansion and vocal resonance. Normal cardiac sounds, abdominal examination showed a palpable spleen and tender liver, results of blood test in the hospital HB 9 grams, neutrophils 8000, and platelets 600000, normal urea and creatinine, Normal transaminases, ALK 400, Gam GGT 500, INR 1, APPT 30, corrected serum calcium 3 mmol/L, ESR 100 CRP 200, parathyroid hormone assay marginally low, serum phosphate normal, 25 hydroxy vitamin D low (30) -1-25 hydroxyl vitamin D elevated, parathyroid related protein negative, urinary calcium elevated. CXR massive right pleural effusion, echocardiogram normal myocardium, valves, and no coronary calcification, normal systolic and diastolic function of right and left ventricles,

and normal pressure. CSF study Normal opening pressure, CSF sugar 2.5 mmol/L (corresponding serum sugar 6 mmol/L) Cells 300 all mononuclear, Protein elevated, CSF saved for viral and bacterial cultures, including Acid fast bacilli, Cryptococcus, listeria, patient started empirically on cephalosporin, ampicillin, gentamycin and dexamethasone. Pleural cavity was punctured and one litter of fluid withdrawn, fluid sent for cells, culture, lactic acid dehydrogenase, albumin, and deaminase, sugar, PH, ProBNP, culture and PCR for tuberculosis, Listeria, Cryptococcus, and Toxoplasmosis, Pleural fluid examination was consistent with Exudate, pleural fluid deaminase level was 219 u/ml (less than 40 u/ml), and pleural biopsy was done and sent for culture.

While patient in the hospital, he started to have continuous fever and testicular pain, patient seen by surgeon who diagnosed epididymo-orchitis, testicular ultrasound supported the diagnosis of epididymo-orchitis, patient taken to theatre and had testicular biopsy and sent for microbiology and culture. Metronidazole was added to his antibiotics, patient seen by infectious disease specialist who added interferon gamma assay to pleural fluid and serum, and advised to start on rifampicin, INH, Ethambutol, Pyrazinamide and dexamethasone. After two weeks, result of pleural biopsy confirmed mycobacterium tuberculosis sensitive to rifampicin and resistant to pyrazinamide and sensitive to rifampin, and INH, interferon gamma assay was strongly positive, patient was started on Rifampin, INH, Ethambutol and levofloxacin for 12 months. Patient started to improve after 4 month of quadruple therapy, repeated induced sputum for mycobacterium was negative, Patient was diagnosed as TB meningitis, epididymo-orchitis and pulmonary TB due to disseminated TB related BCG.

### Discussion

BCG is an attenuated live strain of mycobacterium bovis which is used as a vaccine to prevent tuberculosis in low-income country [1]. People vaccinated with BCG develop positive tuberculin skin test (Monteux test). BCG was part of Australian vaccination regimen till 1989, because of decreased incidence of TB in Australia, it was removed. BCG is currently recommended for people of high risk of TB [2,3].

BCG had shown good efficacy to prevent fulminant TB in young children. BCG still used as a test to exclude latent TB in some countries where the exposure risk is low. BCG had been replaced by interferon gamma release assay (IGRA) as it is more specific for latent TB, it is also a common test to do for patients starting on rituximab and other immunotherapy in patient at risk to develop TB. Intravesical BCG had proven efficacy as an adjunct treatment for intermediate and high grade non muscle invasive bladder cancer, despite its proven efficacy, it can cause disseminated Tuberculosis, [4,5] clinicians should have a low threshold to treat for disseminated TB, in patients treated with intravesical BCG in the past if they developed pulmonary, meningeal or disseminated symptoms of infections and continue until they rule out metastasis due to primary disease (urothelial bladder cancer) or disseminated infection, severe symptoms of BCG include hepatitis and pan cytopenia. The mode of dissemination could be due to haematogenous dissemination from the bladder or type 1V hypersensitivity reaction, the response to steroid treatment had supported the notion of delayed allergic reaction, there is no established measures to avoid dissemi-

nated TB related BCG, but patients who had the injection close to surgery site and those who had repeated catheterization or had bladder biopsy are at increased risk of disseminated BCG related TB infection, non-caseating granuloma detected by histology, positive acid-fast bacilli and mycobacterium bovis by molecular biology almost confirm the diagnosis, dissemination can happen six months to few years after intravesical instillation of BCG. The incidence of systemic complications ranged from 3% to 4.3%, common organs to develop granuloma are liver and lung, corticosteroids had been reported to ameliorate the systemic symptoms in most patients [6-8]. BCG should only be used as an adjunct therapy to TURPT in high grade non-invasive cancer due to unfavourable risk of disseminate Tuberculosis [9,10]. The optimum dose of BCG, optimal frequency and duration differs among urologists. The standard of care is 6 weekly injections as an induction dose followed by a maintenance dose of one injection every three months for one year. Most of the BCG tested vaccine strains are susceptible to all antituberculosis drugs apart from Pyrazinamide and this should be taken into consideration when starting empirical treatment. There is invitro evidence that BCG vaccine strains that have lost region of deletion 2(RD2) are susceptible to macrolides whereas those retained RD2 are resistant, Different strains are used in BCG and this might have impact on the choice of empirical antituberculosis treatment [11-13].

### References

1. Australian Immunisation handbook. Tuberculosis. Canberra, ACT: DOH, 2018.
2. Hussey G, Hawkrigde T, Hanekom W, childhood tuberculosis: old and new vaccines. Paediatr Rep Rev 2007; 8: 148-54.
3. Turnbull FM, McIntyre PB, Achat HM, et al. National study of adverse reactions after vaccination with Bacille Calmette - Guerin. Clin Infect Dis 2002; 34: 447-53.
4. Noguera-Ortega E, Julian E. Mycobacteria- derived for the treatment of urological and renal cancers. Mycobacterium-Res Dev, 2018; 305-324.
5. Gan C, Mostafid H, Khan MS, Lewis DJM. BCG immunotherapy for bladder cancer-the effects of substrain differences. Nat Rev Urol. 2013; 10: 580-588.
6. Brausi M, Oddens J, Sylvester R. side effects of Bacillus Calmette – Guerin (BCG) in the treatment of intermediate and high-risk Ta T1 papillary carcinoma of the bladder: Results of the EORTC Genito- urinary cancers group randomised phase 3 study comparing one third dose with one full dose. Eur Assoc Urol. 2014; 65: 69-76.
7. Krajewski W, Matuszewski M, Poletajew J, Zdrojowy R, Kolodziej A. Are there differences in toxicity and efficacy between various Bacillus Calmette -Guerin strains in bladder cancer patients? analysis of 844 patients, urol Int. 2018; 101: 277-384.
8. Lamm DI, Van der Meijden PM, Morales A et al. incidence and treatment of complications of Bacillus Calmette- Guerin intravesical therapy in superficial bladder cancer. J urol. 1992; 147: 596-600.
9. Menke JJ, Heins JR. Epididymo- orchitis following intravesical Bacillus Calmette- Guerin Therapy Ann pharmacother. 2000; 34: 479-82.
10. Hoag N, Pommerville PJ, Kibsey PC, et al. Tuberculous epididymitis Following intravesical Bacillus Calmette – Guerin immuno-

---

therapy, Can J Urol. 2009; 50: 67-9.

11. foster DR. Miliary Tuberculosis: A complication of Intravesical BCG Treatment. Australia Radiol. 1998; 167-8.
12. Ersoy O, Aran R, Aydinli M, et al. Granulomatous hepatitis after intravesical BCG treatment for bladder cancer. Indian J Gastroenterol. 2006; 25: 258-9
13. Durek C, Rusch -Gerdes S, Jocham D, et al. sensitivity of BCG to Modern antibiotics. Eur Urol C. 2000; 37: 21-5.